Los Angeles Capital Management
CARM

Los Angeles Capital Management’s Carisma Therapeutics CARM Stock Holding History

Los Angeles Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,633
Closed -$44K – 1341
2022
Q1 		$44K Hold
3,633
– – ﹤0.01% 1400
2021
Q4 		$59K Sell
3,633
-39
-1% -$785 ﹤0.01% 1375
2021
Q3 		$58K Hold
3,672
– – ﹤0.01% 1459
2021
Q2 		$339K Buy
+3,672
New +$234K ﹤0.01% 1346

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Los Angeles Capital Management's CARM Position: Q2 2022 in Review

Los Angeles Capital Management sold out of Carisma Therapeutics (CARM) in Q2 2022, closing a stake of 3,633 shares — an estimated $44K sold.

Los Angeles Capital Management first reported a position in CARM in Q2 2021 and held it in 4 quarters. The position peaked at $339K in Q2 2021. 73 funds tracked by Wall St. Rank hold CARM as of Q2 2022.

  • Los Angeles Capital Management reported no remaining Carisma Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Los Angeles Capital Management sold 3,633 Carisma Therapeutics shares in Q2 2022, an estimated $44K.
  • Los Angeles Capital Management first reported a position in Carisma Therapeutics in Q2 2021 and held it in 4 quarters.
  • Los Angeles Capital Management's Carisma Therapeutics position peaked at $339K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2022.

Based on Los Angeles Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.